Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WP 1066

Next Previous
Drug Profile

WP 1066

Alternative Names: WP-1066

Latest Information Update: 27 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moleculin Biotech
  • Developer Emory University; Moleculin Biotech; University of Texas M. D. Anderson Cancer Center; WPD Pharmaceuticals
  • Class Amides; Antineoplastics; Halogenated hydrocarbons; Nitriles; Pyridines; Small molecules
  • Mechanism of Action Hypoxia inducible factor 1 inhibitors; Proto-oncogene protein c-myc inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioma

Highest Development Phases

  • Phase II Glioblastoma
  • Phase I/II Brain metastases; Pancreatic cancer
  • Phase I Glioma; Medulloblastoma
  • Preclinical Cancer
  • Discontinued Acute myeloid leukaemia; Eye neoplasms

Most Recent Events

  • 14 May 2025 Preclinical trials in Cancer in USA (IV), before May 2025
  • 11 Jun 2024 Discontinued - Preclinical for Acute myeloid leukaemia (Combination therapy) in USA (PO) before June 2024 (Moleculin Pipeline, June 2024)
  • 11 Jun 2024 Discontinued - Preclinical for Eye neoplasms in USA (PO) before June 2024 (Moleculin Pipeline, June 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top